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Xdetermining the best time to refer these patients for lung or
heart–lung transplantation.17
The present series included 14 patients with CTEPH. Of
these 14 patients, 11 were not candidates for pulmonary
endarterectomy because distal disease and 3 had undergone
pulmonary endarterectomy at other institutions 6 to 14
years before their referral to our program for lung transplan-
tation. Since the start of our pulmonary endarterectomy
program in 2005, the indications for surgery have evolved.
We currently considered pulmonary endarterectomy for all
patients with evidence of chronic thromboembolic disease
localized in the segmental arteries or more proximally on
the pulmonary angiogram and/or CT pulmonary angiogram
regardless of the degree of right ventricular dysfunction or
the severity of the pulmonary vascular resistance. Thus,
very few patients with CTEPH have been referred for
lung transplantation in our institution since 2008.14
The present study had the limitations of a retrospective
data collection from a single center, including the analysis
of relatively small number of patients, inherent selection
bias, and the potential for missing data. We also included
all patients with CTD and mean pulmonary artery pressure
greater than 25 mmHg associated with a total lung capacity
greater than 60%. Although this definition has been used
by other groups studying patients with PAH diagnosed
with CTD, we did not re-review the CT scans to document
the degree of interstitial lung disease.18,19 Considering the
good results observed with this group of patients in the
present series, future prospective multicenter studies
should be performed to confirm our findings and analyze
patients with CTD in more detail.
In conclusion, our results have demonstrated that, in our
experience, 32% of patients with PAH referred for lung
transplantation are listed for transplantation and 25%
undergo transplantation. The 30-day mortality improved
over time for all categories of patients with PAH, although
the long-term outcomes remained unchanged. In contrast,
the waiting list mortality varied largely with the underlying
cause of PAH. The waiting list mortality was 34% in
patients with CTD-PAH but 0% for patients with iPAH
in the most recent cohort of patients. Patients with CTD-
PAH had excellent early and long-term outcomes after
lung transplantation and should potentially be more aggres-
sively treated on the waiting list, using ECLS if necessary.References
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Dr Kenneth R. McCurry (Cleveland, Ohio). Marc, that was
a very nice presentation and a very nice paper, and I would like
to congratulate you and the rest of your colleagues at the Univer-
sity of Toronto for the very nice manuscript you provided.
This is a rather large series of patients, at least by lung transplant
standards, and certainly for the orphan diagnosis of PAH for trans-
plantation from a very experienced center, the University of
Toronto. You demonstrate significantly improving 30-day out-
comes over a span of 14 years, and I would say excellent long-
term outcomes as well, so you are certainly to be congratulated
for that. I have 3 questions, Marc, regarding your approach and
how you achieved these very good outcomes. First, if I recall
correctly, you demonstrated a reduction in 30-day mortality fromery c April 2012
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X24% in your early era to 6% in the later era, with a fairly low mor-
tality of 5% in double-lung and 8% in heart–lung transplantations.
I think in your manuscript you attribute this to improved postoper-
ativemanagement. I wonder if you could enlighten us onwhat your
approach is and how you specifically have addressed these pa-
tients. As you know, a number of these patients have significant
right ventricular dysfunction issues and certainly can experience
difficulty perioperatively with primary graft dysfunction.
Dr de Perrot. Thank you, Ken.
Yes, I agree. I think we have improved our perioperative man-
agement of RV dysfunction over time, and I think that is certainly
what is translating into these results. For all patients with PAH, we
use cardiopulmonary bypass. Postoperatively, there are a number
of issues, I think, that have progressively changed over time.
One is that we don’t try to wake up these patients very early. We
keep them fully sedated for 2 or even 3 days after the surgery, until
the inflammatory condition from the bypass has had time to settle
down, the creatinine, if it rises, tends to normalize, and the lactate
normalizes. That allows us to keep the right ventricle a little bit
more under control. Thus, the lungs usually experience some de-
gree of dysfunction, but by keeping the patient asleep and being
able to manage their fluid status more precisely, you avoid that hy-
perdynamic flow through the lungs, and I think if you wait 2 or 3
days, you allow the lung to recover a little bit. Also, once the in-
flammatory condition settles down, you can start giving these
patients some Lasix and get them drier. They often come to the
OR with a large fluid overload and I think it’s important to start
getting that fluid out as soon as possible once the inflammatory
condition settles down. If you don’t do that, I think that fluid is pro-
gressively being redistributed from the tissue into the vascular
compartment and will aggravate the edema otherwise.
DrMcCurry.My second question relates really to the selection
of the operation. I think from the data you showed us, the vast
majority of congenital heart disease patients received heart–lung
transplantations, andmost iPAH and CTD patients received double
lungs, but there were a few heart–lung transplantations in that
patient population, and I think you specifically mentioned a low
left ventricular ejection fraction, but do you consider the right ven-
tricle and the degree of RV dysfunction in your decision-making?
Obviously you do, so I’m asking you where you draw the line and
when do you think you need to go to a heart–lung in iPAH patients
or CTD patients.
Dr de Perrot. It’s always a very difficult decision and a point of
a lot of discussion among our group as well. Clearly, if the left ven-
tricle is dysfunctional, there is no doubt. Most of the patients who
hadheart-lung transplantation for iPAHorCTDhadLVdysfunction.
For RV dysfunction, we usually still do a bilateral lung transplant.
Even if the RV is significantly dysfunctional, wewill still do a bilat-
eral lung transplant. I don’t think we have ever done a heart-lung be-
cause the RV was too dysfunctional. But it has always led to some
discussion in our group. At this point, I don’t think we have enough
evidence as to when the RV is too far gone and when the RV is fi-
brotic. The RV has a good capability to recover after the surgery,
but itmight not fully recover, and certainly it contributes to somedif-
ficulty perioperatively. Someof the difficulty is to see how strong the
RV is, and I don’t think the cardiac index or other hemodynamic pa-
rameters allow you to make a decision as to the strength of the RV.
The B-type natriuretic peptide (BNP) or maybe the magneticThe Journal of Thoracic and Caresonance imaging in the future will allow us to have a better idea
of the myocardium in the RV, but at this point I don’t think we
have enough data to really tease out the function of theRV. The other
parameter is the LV dysfunction. If the LV is dysfunctional on the
echocardiographic, then there is no doubt. But what you can see as
well is that the LV can beworking preoperatively just because there
is no flow going to the LV, and once you unload the pulmonary vas-
culature, the cardiac output to the LV increases and the LV becomes
dysfunctional postoperatively. That has been well described. Partic-
ularly in Vienna,Walter Klepetko described that a few years ago. So
theLVgets somedegree of atrophy because of the pulmonary hyper-
tension, and it’s also something that’s difficult to tease out preoper-
atively because it’s part of the same problem, I think.
Dr McCurry. You have a difficult dilemma sometimes and no
clear answer.
I have one final question about your bridging strategies. The
data you demonstrated, Marc, showed us an increasing willingness
to bridge patients with PAH to lung transplantation. I think 7%
of your population was bridged, and all in the past 5 years. Obvi-
ously, you and other groups in Europe have led with the use of the
Novalung, and there are a lot of strategies to try to bridge these
patients—VV-ECMO, VA-ECMO, balloon septostomy with
VV-ECMO, Novalung. Can you give us a bit of insight into what
your program thoughts are right now?
Dr de Perrot. Yes. What we mostly use in these patients, or
what we use when we can, is the Novalung connected between
the pulmonary artery and the left atrium. We use the oxygenator,
the Novalung, the membrane without any pump. The RV creates
the pump to generate the flow through the Novalung, and that al-
lows unloading of the RVand creates a right-to-left shunt with ox-
ygenation of the blood, which really allows the patient to stabilize
immediately once it’s connected. Also, because of the central can-
nulation, it allows the patients to be mobilized.
Once they are extubated and have awakened from the surgery,
they can be mobilized until their transplant. We even currently
have 1 patient who has been on the PA–LA Novalung for 3 months
and is still waiting. So you can really bridge these patients for
a number of weeks at least, if not months, by that mechanism. It
requires a sternotomy and you can have some difficulty with bleed-
ing, which eventually needs to be controlled, but once things settle
down, it’s a very nice way to bridge them. The alternative is the
VA-ECMO, or the group at the University of Maryland has de-
scribed the VV-ECMO with an interatrial shunt to generate the
flow through the left cavity of the heart. But certainly I would
never recommend doing any LVAD for these patients. By putting
an LVAD without any oxygenator, you’re facing a major problem
with potential hypoxemia, as well as bleeding from the cannulas
due to the high PA pressure, and you really have to bypass the
lungs with whatever technique you use.
Dr McCurry. Thank you, Marc. It was a nice paper and excel-
lent outcomes.
Dr Andrew C. Chang (Ann Arbor, Mich).Dr. de Perrot, I thank
you and your colleagues for presenting your experience at Toronto.
You had pointed out that about 22%, one fifth of the patients in
your cohort, were thought initially to be too well for transplanta-
tion. Could you comment on your selection criteria? As you
have noted this is a difficult population to decide on listing for
transplantation, and I would appreciate your insights in that regard.rdiovascular Surgery c Volume 143, Number 4 917
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XDr de Perrot. Our recommendation is to really assess these
patients early on. At least with the pulmonary hypertension
program at Toronto General, when patients go on Flolan, that is
typically when we assess these patients, and then we watch them
on Flolan, and if they deteriorate on Flolan, and sometimes they
can deteriorate relatively quickly, wewill be able to list them emer-
gently and have them ready within a few days, and if they do well,
then we have the assessment data that we can maintain for several
years, and if they come to transplant later, then you repeat a few of
the investigations, but at least they know what transplant means,
we know they are eligible, and we can list them relatively quickly
that way. That’s what our recommendation has been. But despite
that, what our analysis shows is that you still have 10% to 15%
of the patients who die even before reaching an assessment. There
are fewer patients dying now between the assessment and the list-
ing. That’s something that has decreased progressively. But there
are still 10%, 15% of the patients who are referred way too late
and they don’t even make it to an assessment because of the late
referral, and that’s really something that we try to avoid by having
an early referral. But it’s always a very difficult decision as towhen
to list them, when is the right time.918 The Journal of Thoracic and Cardiovascular SurgDr Chang. Do you think there’s any utility in using a biochem-
ical marker? Could you elaborate on your use of serum BNP
measurement, for example?
Dr de Perrot. Yes. We are using BNP more and more. BNP has
been very useful to tease out some of the responses to the PH ther-
apy and to seewhether it translates into better outcome if your BNP
decreases on any of the PH medications. So we use it as a marker.
We don’t really use it once they are on thewaiting list. If the BNP is
high or the BNP goes up, that certainly can be a sign that suggests
that you should potentially list these patients. We should probably
use the BNPmore often.We have done only a few cases. But one of
the difficult decisions is alsowhen you should bridge these patients
with the Novalung, extracorporeal life support. Initially, we were
really pushing the limit by doing that too late, and 1 patient even
arrested on theway to the operating room. I think as we have gotten
more confident with ECLS, we have been bridging these patients
earlier on, and I think BNP is also one parameter you can follow
once you have to put the patients on inotropes. If their BNP doesn’t
come down or stays very high, this potentially would be an indica-
tion to go on ECLS to do it in a better condition than urgently in the
middle of the night.ery c April 2012
